{
  "docId": "019de076-cd1b-731e-ae5e-e1dc823ccd70",
  "docSlug": "8f301a1a54ee099c965687c909e40052",
  "documentTitle": "Equillium | Investor Presentation Deck | 40 slides",
  "authorId": "equillium",
  "authorName": "Equillium",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 40,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses western blot data to demonstrate the mechanism of action difference between the competitor (Ruxolitinib) and the company's drug (EQ101).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-cd1b-731e-ae5e-e1dc823ccd70/19",
  "deckHref": "/decks/019de076-cd1b-731e-ae5e-e1dc823ccd70",
  "deckJsonHref": "/decks/019de076-cd1b-731e-ae5e-e1dc823ccd70.json",
  "deckAnchorHref": "/decks/019de076-cd1b-731e-ae5e-e1dc823ccd70#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.94,
        "x": 0.03,
        "y": 0.0018
      },
      "kind": "callout",
      "text": "JAKi suppression of cytokine signaling is incomplete, while EQ101 inhibits the multiple downstream pathways for complete suppression of cytokine signaling",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa8185e5-07e7-4fee-bf90-61262c9a6bbe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.75,
        "x": 0.2,
        "y": 0.0045
      },
      "kind": "chart",
      "text": "Western blot data comparing pathway inhibition",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "65898e86-5066-4717-9c24-80685cde3477",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.9,
        "x": 0.05,
        "y": 0.0045
      },
      "kind": "image",
      "text": "Diagrams showing receptor signaling pathways for Ruxolitinib vs EQ101",
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9811eaf7-13b3-4880-b8d9-ff669576081e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.4,
        "x": 0.12,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "In-house data and Frohna et al., Alopecia Areata Research Summit, New York, New York, 2018",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fa20a202-7d3d-4729-990a-f4aee473f492",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.94,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "EQ101: More Complete Downstream Signal Inhibition Versus JAKi",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "33fad0f0-6ff3-4556-b9e3-79ae90bd2a8c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}